acetyl cholinesterase

acetyl cholinesterase (a·sēˑ·tl kōˈ·l·neˑ·st·rās),

n enzyme found at both voluntary and parasympathetic nerve endings that hydrolyzes the acetylcholine byproduct of nerve impulses into acetate and choline.
References in periodicals archive ?
The first chemical change is the conversion of sulfur to oxygen, producing a more potent acetyl cholinesterase inhibitor.
Rapeseed oil is an acetyl cholinesterase inhibitor.
Galanthamine was used as standard and it showed inhibition of acetyl cholinesterase with an [IC.
Aldicarb, a carbamate pesticide, also exerts its toxicity through acetyl cholinesterase inhibition.
These were acetyl cholinesterase inhibitors (Acheis) - Aricept (donepezil), Exelon (rivastigmine) and Reminyl (galantamine).
Nice decided that acetyl cholinesterase inhibitors - drugs such as Aricept, Reminyl and Exelon - should not be given to patients with mild Alzheimer's on the NHS.
After over two years of deliberations over the value of acetyl cholinesterase inhibitors for all patients diagnosed with Alzheimer's disease, it is a sad day for patients and their carers" said John Freeman, Managing Director of Shire's UK commercial operation.
Many studies have shown that the enzyme acetyl cholinesterase contributes to the onset of Alzheimer's disease, and thus the ability to inhibit the enzyme's activity has become accepted as a means of possible prevention of further deterioration.
Second, the outcome measures in the industry studies were peripheral red blood cell acetyl cholinesterase (AChE) levels, a symptom checklist, and blood pressure (AMVAC 1997; Haines 1971; Wyld et al.
Even though the improvement of the cholinergic transmission of the patients suffering from Alzheimer's is necessary (the basis of most of today's therapies), targeting acetyl cholinesterase solely is certainly not sufficient, in relationship to the numerous pathways involved in Alzheimer's disease pathology.
He received one of the acetyl cholinesterase inhibitors (AChEIs) - Aricept (donepezil), Exelon (rivastigmine) and Reminyl (galantamine) - now the focus of the legal challenge by the Alzheimer's Society.
Nice had decided back in 2004 that the drugs, acetyl cholinesterase inhibitors, were not a cost-effective way of treating the early stages of Alzheimer's.